Cancer, one of the most life-threatening diseases, is projected to affect over 35 million people worldwide in 2050 — 77% more ...

"Metastatic breast cancer is where breast cancer moves from the origin in the breast through the blood, and through the lymph ...

NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment ...

DNA testing revolutionizes metastatic castration-resistant prostate cancer prognosis, improving patient outcomes with faster ...

The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's ...

GRAIL (GRAL) announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer, or ...

Lung12, patients will be screened with the GRAIL assay prior to surgery to inform eligibility for post-surgery randomization to an adjuvant treatment regimen ( NCT06564844 ). Assay performance was ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient.

PeCan-Seq enables sensitive, non-invasive ctDNA analysis for pediatric cancers, with high accuracy for hematologic ...

New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung ...

Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...

Arnab Basu, MD, MPH, FACP, explains why sensitivity might be higher in urothelial cancer vs other genitourinary cancers.